Compare BBNX & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBNX | WD |
|---|---|---|
| Founded | 2015 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 997.9M | 1.1B |
| IPO Year | 2025 | 2010 |
| Metric | BBNX | WD |
|---|---|---|
| Price | $16.91 | $31.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | $24.24 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 912.1K | 530.8K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 8.33% |
| EPS Growth | ★ 78.95 | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $100,251,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | $25.74 | $9.25 |
| Revenue Next Year | $44.51 | $9.48 |
| P/E Ratio | ★ N/A | $59.36 |
| Revenue Growth | ★ 53.94 | 8.99 |
| 52 Week Low | $8.80 | $31.40 |
| 52 Week High | $32.71 | $90.00 |
| Indicator | BBNX | WD |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 31.81 |
| Support Level | $15.76 | N/A |
| Resistance Level | $18.20 | $52.37 |
| Average True Range (ATR) | 0.87 | 1.42 |
| MACD | -0.29 | 0.02 |
| Stochastic Oscillator | 24.84 | 6.77 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.